NCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
56 trialsNCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT05960630 2023-11-18
MIRRORS-RCTP
Royal Surrey County Hospital NHS Foundation Trust
Phase NA Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT03363867 2023-08-07
BEACON
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT05801783 2023-04-06
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05792254 2023-03-31
Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer
Ruijin Hospital
Phase NA Unknown
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT03430700 2023-01-30
PROMPT
University College, London
Phase 2 Unknown
NCT02125513 2022-12-30
GOGER-01
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Unknown
NCT05622890 2022-11-21
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03540017 2022-11-02
HIPEC After Initial CRS in Patients Who Have Received NACT
Northwell Health
Phase 1 Unknown
NCT05043402 2022-08-15
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
OncXerna Theraputics, Inc.
Phase 3 Unknown
NCT02033616 2022-04-25
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Aivita Biomedical, Inc.
Phase 2 Unknown
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04375956 2021-12-20
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT00108745 2021-09-30
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 3 Unknown
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT01611766 2021-06-10
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Shanghai Gynecologic Oncology Group
Phase 3 Unknown
NCT04846842 2021-04-19
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT00652119 2020-08-19
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Massachusetts General Hospital
Phase 1 Unknown
NCT03150121 2020-02-26
BEDOCA
Sheba Medical Center
Phase NA Unknown
NCT03693248 2019-12-10
ROCOCO
Seoul National University Hospital
Phase 3 Unknown
NCT03373058 2019-11-06
EHTASEOCCS
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT04001023 2019-08-07
OVANOX
Turku University Hospital
Phase NA Unknown
NCT04029909 2019-07-23
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 1 Unknown
NCT00958698 2019-03-12
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase NA Unknown
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT03283943 2018-07-11
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
British Columbia Cancer Agency
Phase 1 Unknown
NCT03188159 2018-03-29
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT00719303 2018-02-19
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Unknown
NCT02534922 2018-02-14
ProlantaOC
Oncolix, Inc.
Phase 1 Unknown
NCT03180177 2018-01-24
EHNPCTASEOC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT02595021 2016-07-26
Total/Subtotal Colectomy in Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Unknown
NCT00532194 2015-09-23
ICON6
Medical Research Council
Phase 3 Unknown
NCT02435186 2015-05-06
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Phase 2 Unknown
NCT00003064 2014-01-06
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003560 2014-01-06
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003634 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004064 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005025 2013-11-06
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00838656 2013-09-17
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00601406 2013-08-26
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT01100372 2013-08-26
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00305838 2013-08-12
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
National Cancer Institute (NCI)
Phase 2 Unknown